FrancophonIA/ELRC3.0 huggingface dataset:
English: Talk to your doctor or nurse before you are given Gazyvaro if: · you have an infection, or have had an infection in the past which lasted a long time or keeps coming back · you have ever taken, or been given, medicines which affect your immune system (such as chemotherapy or immunosuppressants) · you are taking medicines for high blood pressure or medicines used to thin your blood - your doctor might need to alter how you take these · you have ever had heart problems · you have ever had brain problems (such as memory problems, difficulty moving or feeling sensations in your body, eyesight problems) · you have ever had breathing problems or lung problems · you have ever had “hepatitis B” - a type of liver disease · you are due to have a vaccine or you know you may need to have one in the near future.
Maltese: Huwa jimmira speċifikament iċ-ċirku ekstraċellulari tal-antiġen CD20 transmembraniku fuq il-wiċċ ta' limfoċiti pre-B u B maturi mhux malinni u malinni, iżda mhux dak fuq ċelluli staminali ematopoetiċi, ċelluli pro-B, ċelluli normali tal-plażma jew tessut normali ieħor. Glycoengineering tal-parti Fc ta' obinutuzumab tirriżulta f'affinità ogħla għar-riċetturi FcɣRIII fuq iċċelluli ta' rispons immuni bħal ċelluli qattiela naturali (NK - natural killer), makrofaġi u monoċiti meta mqabbel ma 'antikorpi mhux glycoengineered.
English: What Gazyvaro is
Maltese: Gazyvaro.
English: How to store Gazyvaro
Maltese: X'inhu Gazyvaro
English: Offspring exposure on day 28 post-partum suggests that obinutuzumab can cross the blood-placenta barrier.
Maltese: Esponiment tal-frieħ f'jum 28 wara t-twelid jissuġġerixxi li obinutuzumab jista' jaqsam il-barriera ta' bejn id-demm u l-plaċenta.
English: Chronic lymphocytic leukaemia · You will be given 6 treatment cycles of Gazyvaro in combination with another medicine for cancer called chlorambucil.
Maltese: • Inti se tingħata 6 ċikli ta' kura ta' Gazyvaro flimkien ma' mediċina oħra għall-kanċer imsejħa chlorambucil.
English: Corticosteroid premedication is recommended for patients with FL and mandatory for CLL patients in the first cycle (see Table 1).
Maltese: Medikazzjoni minn qabel b'kortikosterojdi hija rakkomandata għal pazjenti b'FL u obbligatorja għall-pazjenti b'CLL fl-ewwel ċiklu (ara Tabella 1).
English: Do not use other diluents such as glucose (5%) solution.
Maltese: Tużax dilwenti oħrajn bħal soluzzjoni ta' glucose (5%).
English: Gazyvaro should be prepared by a healthcare professional using aseptic technique.
Maltese: Gazyvaro għandu jiġi ppreparat minn professjonist fil-kura tas-saħħa permezz ta' teknika asettika.
English: The number of fatal haemorrhagic events was balanced between the treatment arms; however, all of the events in patients treated with Gazyvaro were reported in Cycle 1.
Maltese: In-numru ta' avvenimenti emorraġiċi fatali kien bilanċjat bejn il-gruppi ta' kura; madankollu, l-avvenimenti kollha f'pazjenti kkurati b'Gazyvaro kienu rrappurtati f'Ċiklu 1.
English: B-cell counts returned to normal levels in the offspring, and immunologic function was restored within 6 months of birth.
Maltese: L-għadd ta' ċelluli B reġa' lura għal-livelli normali fil-frieħ, u l-funzjoni immunoloġika reġgħet lura għannormal fi żmien 6 xhur mit-twelid.
English: In case of exposure during pregnancy, depletion of B-cells may be expected in infants due to the pharmacological properties of the product.
Maltese: F'każ ta' esponiment waqt it-tqala, jista' jkun mistenni tnaqqis komplut taċ-ċelluli B fi trabi minħabba l-kwalitajiet farmakoloġiċi tal-prodott.
English: In CLL patients who received the combined measures for prevention of IRRs (adequate corticosteroid, oral analgesic/anti-histamine, omission of antihypertensive medicine in the morning of the first infusion, and the Cycle 1 Day 1 dose administered over 2 days) as described in section 4.2, a decreased incidence of IRRs of all Grades was observed.
Maltese: F'pazjenti b'CLL li rċevew il-miżuri kombinati għall-prevenzjoni ta' IRRs (kortikosterojd adegwat, analġeżiċi/antistaminiċi orali, ommissjoni ta' mediċini kontra lpressjoni għolja fl-għodwa tal-ewwel infużjoni, u d-doża ta' Ċiklu 1 Jum 1 mogħtija fuq jumejn) kif deskritt f'sezzjoni 4.2, kienet osservata inċidenza inqas ta' IRRs ta' kull Grad.
English: The most frequently observed adverse drug reactions (ADRs) in patients receiving Gazyvaro were IRRs, which occurred predominantly during infusion of the first 1,000 mg. IRRs may be related to cytokine release syndrome which has also been reported in Gazyvaro treated patients.
Maltese: L-aktar reazzjonijiet avversi tal-mediċina (ADRs - adverse drug reactions) osservati b'mod frekwenti f'pazjenti li kienu qed jirċievu Gazyvaro kienu IRRs, li fil-biċċa l-kbira seħħew waqt l-infużjoni talewwel 1,000 mg.
English: You may be more likely to get an infection during and after treatment with Gazyvaro.
Maltese: Jista' jkollok probabbiltà akbar li taqbdek infezzjoni matul u wara trattament b'Gazyvaro.
English: Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen GERMANY
Maltese: D-79639 Grenzach-Wyhlen
English: The Gazyvaro treatment
Maltese: Trattament b'Gazyvaro
English: In the QLQC30 and QLQ-CLL-16 questionnaires conducted during the treatment period, no substantial difference in any of the subscales was observed.
Maltese: Fil-kwestjonarji QLQC30 u QLQ-CLL-16 li saru matul il-perjodu ta' kura, ma kienet osservata l-ebda differenza sostanzjali fi kwalunkwe wieħed mis-sottoskali.
English: The population pharmacokinetic analysis of obinutuzumab showed that age did not affect the pharmacokinetics of obinutuzumab.
Maltese: Ma kinitx osservata tossiċità renali b'relazzjoni kawżali għal obinutuzumab fil-bnedmin.
English: Gazyvaro was given by intravenous infusion as a dose of 1,000 mg on Days 1, 8 and 15 of Cycle 1, on Day 1 of Cycles 2-6, and in patients who did not have disease progression, once every two months for two years or until disease progression (whichever occurs first).
Maltese: Gazyvaro ingħata permezz ta' infużjoni fil-vini bħala doża ta' 1,000 mg f'Jiem 1, 8 u 15 ta' Ċiklu 1, f'Jum 1 ta' Ċikli 2-6, u f'pazjenti li ma kellhomx progressjoni tal-marda, darba kull xaharejn għal sentejn jew sal-progressjoni tal-marda (skont liema jseħħ l-ewwel).
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1,000 mg/40 mL
Maltese: 1,000 mg/40 mL
English: 2 e.g. 1,000 mg acetaminophen/paracetamol
Maltese: Attivazzjoni mill-ġdid tal-epatite B
English: The incidence of IRRs was higher in the Gazyvaro plus chlorambucil arm compared to the rituximab plus chlorambucil arm.
Maltese: L-inċidenza ta' IRRs kienet ogħla fil-grupp ta' Gazyvaro flimkien ma' chlorambucil meta mqabbel mal-grupp ta' rituximab flimkien ma' chlorambucil.
English: To ensure differentiation of the two infusion bags for the initial 1,000 mg dose, it is recommended to utilise bags of different sizes to distinguish between the 100 mg dose for Cycle 1 Day 1 and the 900 mg dose for Cycle 1 Day 1 (continued) or Day 2.
Maltese: Biex tiġi żgurata differenzazzjoni taż-żewġ boroż tal-infużjoni għad-doża tal-bidu ta' 1,000 mg, huwa rakkomandat li jintużaw boroż ta' daqsijiet differenti biex issir distinzjoni bejn id-doża ta '100 mg għal Ċiklu 1 Jum 1 u d-doża ta' 900 mg għal Ċiklu 1 Jum 1 (kontinwazzjoni) jew Jum 2.
English: Antiviral and antifungal prophylaxis should also be considered (see section 4.2).
Maltese: Għandha tiġi kkunsidrata ukoll profilassi antivirali u kontra l-moffa (ara sezzjoni 4.2).
English: Psychiatric disorders Very common
Maltese: Disturbi psikjatriċi Komuni ħafna
English: Cycles 2-6 or
Maltese: Ċikli 2-6 jew
English: The rate of the infusion can be escalated in increments of 50mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Maltese: Ir-rata talinfużjoni tista' tiżdied b'inkrementi ta' 50 mg/siegħa kull 30 minuta sa rata massima ta' 400 mg/siegħa.
English: Exposure in utero to obinutuzumab and vaccination of infants with live virus vaccines
Maltese: Esponiment in utero għal obinutuzumab u tilqim ta' trabi b'vaċċini b'virus ħaj
English: Efficacy results in the FL population are shown in Table 9.
Maltese: Riżultati tal-effikaċja filpopolazzjoni ta' FL huma murija fit-Tabella 9.
English: Recovery of B-cells was observed within 12-18 months of follow up in 35% (14 out of 40) of patients without progressive disease and 13% (5 out of 40) with progressive disease.
Maltese: Irkupru taċ-ċelluli B kien osservat fi żmien 12-18-il xahar ta' segwitu f'35% (14 minn 40) tal-pazjenti mingħajr marda progressiva u fi 13% (5 minn 40) ta' dawk b'marda progressiva.
English: Cycles 2-6 or 2-8 - this will be just one dose of Gazyvaro in the 28 or 21 days depending on which other cancer medicines are given together with Gazyvaro: · Day 1 - full dose (1,000 mg).
Maltese: Ċikli 2-6 jew 2-8 - dan se jkun biss doża waħda ta' Gazyvaro f'jum 28 jew 21skont liema mediċini oħra għall-kanċer jingħataw flimkien ma' Gazyvaro:
English: While fatal haemorrhagic events occurred in less than 1% of patients; none of the fatal adverse events occurred in Cycle 1.
Maltese: Filwaqt li avvenimenti emorraġiċi fatali seħħew f'inqas minn 1% tal-pazjenti; l-ebda wieħed mill-avvenimenti avversi fatali ma seħħ f'Ċiklu 1.
English: Mitigation measures to reduce IRRs should be followed (see section 4.2).
Maltese: Għandhom jiġu segwiti miżuri ta' mitigazzjoni biex jitnaqqsu IRRs (ara sezzjoni 4.2).
English: Thrombocytopenia occurred more frequently in Cycle 1 in the Gazyvaro plus chemotherapy arm. Thrombocytopenia occurring during or 24 hours from end of infusion (acute thrombocytopenia) was more frequently observed in patients in the Gazyvaro plus chemotherapy arm than in the comparator arm.
Maltese: Waqt kura b'Gazyvaro kienet osservata tromboċitopenija severa u ta' periklu għall-ħajja inkluż tromboċitopenija akuta (li sseħħ fi żmien 24 siegħa wara l-infużjoni).
English: Chest pain
Maltese: U LUŻU
English: Best Overall Response (BOR) (IRC-assessed) No. of patients included in the analysis Responders (%) (CR/PR) Difference in response rate (95% CI) p-value (Cochran-Mantel-Haenszel test) Complete Responders (%) Partial Responders (%) Stable Disease (%) Duration of response (DOR) (IRCassessed) No of patients included in the analysis No. (%) of patients with event Median duration (months) of DOR (95% CI)
Maltese: Tul ta' rispons (DOR - duration of response) (evalwat minn IRC) Numru ta' pazjenti inklużi fl-analiżi Numru (%) ta' pazjenti b'avveniment Tul medjan (xhur) ta' DOR (CI ta' 95%)
English: These trials investigated Gazyvaro in combination with chlorambucil for CLL and with bendamustine, CHOP or CVP followed by Gazyvaro maintenance therapy for iNHL.
Maltese: Kienu rrappurtati każijiet ta' perforazzjoni gastrointestinali f'pazjenti li kienu qed jirċievu Gazyvaro, il-biċċa l-kbira f'iNHL.
English: Unopened vial
Maltese: Bijotrasformazzjoni
English: Forty-two percent of patients enrolled had both a CrCl < 70 mL/min and a comorbidity score of > 6.
Maltese: Tnejn u erbgħin fil-mija tal-pazjenti rreġistrati kellhom kemm CrCl < 70 ml/min kif ukoll punteġġ ta' komorbidità ta' > 6.
English: Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of Gazyvaro as outlined below (see also section 4.4).
Maltese: L-immaniġġjar tal-IRRs għandu mnejn ikun jeħtieġ interruzzjoni temporanja, tnaqqis fir-rata talinfużjoni, jew waqfien tal-kura ta' Gazyvaro kif spjegat taħt (ara wkoll sezzjoni 4.4).
English: Patients with a Grade 3 IRR with the previous infusion OR Patients with lymphocyte counts >25 x 109/L prior to next treatment
Maltese: Pazjenti b'IRR ta' Grad 3 waqt l-infużjoni ta' qabel JEW Pazjenti b'għadd ta' limfoċiti ta' >25 x 109/L qabel it-trattament li jmiss
English: Nespo exists in various strengths, from 10 to 500 micrograms per millilitre.
Maltese: Nespo jeżisti f'diversi qawwiet, minn 10 sa 500 mikrogramma kull millilitru.
English: It contains the active substance darbepoetin alfa.
Maltese: Darbepoetin alfa
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NESPO EPAR summary for the public
Maltese: RAPPORT TA' VALUTAZZJONI PUBBLIKA EWROPEW (EPAR) NESPO
English: This summary was last updated in 09-2007.©EMEA 2007
Maltese: Prodott mediċinali li m'għadux awtorizza©EMEA 2007
English: What is Nespo?
Maltese: Kif jaħdem Nespo ?
English: The most common side effects with Nespo (seen in between 1 and 10 patients in 100) are headache, hypertension (high blood pressure), thrombosis (blood clots), injection site pain, arthralgia (joint pain) and peripheral oedema (fluid retention).
Maltese: L-aktar effetti sekondarji komuni b'Nespo (dehru f'madwar 1 u 10 pazjenti minn kull 100) huma uġigħ ta' ras, pressjoni għolja, trombożi (ċapep tad-demm), uġigħ fis-sit ta' l-injezzjoni, artralġja (uġigħ fil-ġogi) u edema periferali (żamma ta' fluwidu).
English: The types of cancer where Nespo can be used are ‘non-myeloid' (do not affect the bone marrow).
Maltese: It-tipi ta' kanċer fejn jista' jintuża Nespo huma ‘non-myeloid' (ma jaffettwawx il-mudullun).
English: • adults and children over one year of age with anaemia caused by long-term kidney failure, when the body does not produce enough of the natural hormone erythropoietin,
Maltese: • Adulti u tfal ta' aktar minn sena b'anemija ikkaġunata minn indeboliment tal-kliewi fuq tul ta' żmien, meta l-ġisem ma jipproduċix biżżejjed mill-ormon naturali erythropoietin.
English: The dose used depends on why Nespo is used, varying from 0.45 micrograms per kilogram every week (or 0.75 micrograms/kg every other week) in adults and children with kidney failure aged 11 years or older, to 6.75 micrograms/kg every three weeks in cancer patients.
Maltese: Iddoża użata tiddependi fuq għalfejn ħa jintuża Nespo , tvarja minn 0.45 mikrogrammi kull kilogramm kull ġimgħa (jew 0.75 mikrogrammi/kg kull ġimgħa iva u ġimgħa le) fl-adulti u tfal ta' etajiet ta' 11-il sena jew akbar b'indeboliment tal-kliewi, għal 6.75 mikrogrammi/kg kull tlett ġimgħat f'pazjenti bilkanċer.
English: Darbepoetin alfa is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes the cell able to produce darbepoetin alfa.
Maltese: hija magħmula permezz ta' metodu magħruf bħala ‘teknoloġija rekombinanti tad-DNA', li tagħmel liċ-ċellola kapaċi tipproduċi darbepoetin alfa.
English: How has Nespo been studied?
Maltese: Kif ġie studjat Nespo ?
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Nespo's benefits are greater than its risks for the treatment of anaemia associated with chronic renal failure in adults and paediatric patients, and of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Maltese: Il-Kumitat għal Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li l-benefiċċji ta' Nespo huma akbar mir-riskji tiegħu għall-kura ta' anemija assoċjata ma' falliment renali kroniku fladulti u f'pazjenti pedjatriċi, u ta' anemija sintomatika f'pazjenti adulti bil-kanċer b'malinni ‘non-myeloid' li qed jirċievu kimoterapija.
English: Darbepoetin alfa, the active substance in Nespo, acts exactly like the natural erythropoietin made by the body, but it is very slight different in its structure, and this means that darbepoetin alfa has a longer duration of action, and can be given less often than natural erythropoietin.
Maltese: Darbepoetin alfa, is-sustanza attiva f'Nespo , taħdem eżattament bħal erythropoietin naturali magħmul mill-ġisem, iżda hija xi ftit differenti fl-istruttura tagħha, u dan ifisser li darbepoetin alfa għandha tul ta'azzjoni aktar twila, u tista' tingħata inqas ta' spiss minn erythropoietin naturali.
English: The effectiveness of Nespo has been studied in patients with long-term kidney disease, where it was compared with recombinant human erythropoietin in four studies involving over 1,200 patients, and in patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma, where it was compared with placebo (a dummy treatment) in two studies involving 669 patients.
Maltese: L-effettività ta'Nespo ġiet studjata f'pazjenti b'mard tal-kliewi fit-tul, fejn ġie mqabbel ma' erythropoietin rekombinanti tal-bniedem f'erba' studji li jinvolvu aktar minn 1,200 pazjent, u f'pazjenti li qed jirċievu kimoterapija għal kanċer bħal ma' huwa kanċer tal-pulmun, majeloma jew limfoma, fejn tqabbel ma' plaċebo (trattament finta) f'żewġ studji li jinvolvu 669 pazjent.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nespo to Dompé Biotec S.p.A. on 8 June 2001.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida madwar l-Unjoni Ewropea kollha għal Nespo lil Dompé Biotec S.p.A. fit-8 ta' Ġunju 2001.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Maltese: Jekk trid aktar informazzjoni abbażi tar-rakkomandazzjonijiet ta' CHMP, aqra d-Diskussjoni Xjentifika (ukoll
English: A lack of natural erythropoietin is also one of the causes of anaemia in patients receiving chemotherapy.
Maltese: Nuqqas ta' erythropoietin naturali huwa ukoll wieħed mill-kaġuni ta' anemija f'pazjenti li jkunu qed jirċievu lkimoterapija.
English: Nespo works by stimulating the production of red blood cells in the same way as natural erythropoietin.
Maltese: Nespo jaħdem billi jistimola l-produzzjoni ta' ċelloli ħomor tad-demm bl-istess mod bħal erythropoietin naturali.
English: • adult patients with certain types of cancer who are receiving chemotherapy (the medicines used to treat cancer), when the chemotherapy stops the bone marrow producing enough blood cells.
Maltese: • Pazjenti adulti b'ċerti tipi ta' kanċer li qed jirċievu kimoterapija (il-mediċini użati biex jikkuraw il-kanċer), meta l-kimoterapija twaqqaf lill-mudullun milli jipproduċi biżżejjed ċelloli tad-demm.
English: Belgium Cipla Europe Nv
Maltese: Il-Belġju Cipla Europe Nv
English: Nebuliser Suspension
Maltese: Sospensjoni Nebulizzatur
English: Meda Pharma Spol.
Maltese: Is-Slovakkja Meda Pharma Spol.
English: Ucb Pharma Gmbh (Monheim De)
Maltese: Il-Ġermanja Ucb Pharma Gmbh (Monheim De)
English: Sandoz Hungária Kft
Maltese: L-Ungerija Sandoz Hungária Kft
English: 9µg Dose
Maltese: Doża ta' 9 µg
English: Belgium Sandoz N.V.
Maltese: Il-Belġju Sandoz N.V.
English: Medochemie Romania S.R.L.
Maltese: Ir-Rumanija Medochemie Romania S.R.L.
English: Budesonide 0.8mg Capsule
Maltese: Budesonide 0.8mg Kapsula
English: Belgium Chiesi Sa-Nv
Maltese: Chiesi Sa-Nv
English: Janssen-Cilag Gmbh
Maltese: Il-Ġermanja Janssen-Cilag Gmbh
English: 4.5µg Dose
Maltese: Doża ta' 4.5 µg
English: Allen Pharmazeutika Gesellschaft M.B.H.
Maltese: L-Awstrija Allen Pharmazeutika Gesellschaft M.B.H.
English: Netherlands Chiesi Pharmaceuticals B.V.
Maltese: Chiesi Pharmaceuticals B.V.
English: Budesonide 200µg Capsule
Maltese: Budesonide 200 µg Kapsula
English: Clinres Farmacija D.O.O.
Maltese: Il-Kroazja Clinres Farmacija D.O.O.
English: Glaxosmithkline D.O.O., Ljubljana Seretide Diskus
Maltese: Is-Slovenja Glaxosmithkline D.O.O., Ljubljana Seretide Diskus
English: Glaxosmithkline D.O.O., Ljubljana Flixotide
Maltese: Is-Slovenja Glaxosmithkline D.O.O., Ljubljana Flixotide
English: Samtoral Diskus Standard Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose
Maltese: Samtoral Diskus Standard Fluticasone Propionate Doża ta' 250 µg, Salmeterol Doża ta' 50 µg
English: Glaxosmithkline Lietuva Uab
Maltese: Il-Litwanja Glaxosmithkline Lietuva Uab
English: Glaxosmithkline Slovakia S.R.O.
Maltese: Is-Slovakkja Glaxosmithkline Slovakia S.R.O.
English: Salbutamol Sulfate 0.602mg Vial, Flunisolide 0.5mg Vial
Maltese: Salbutamol Sulfate Kunjett ta' 0.602mg, Flunisolide Kunjett ta' 0.5mg
English: Budesonid Novolizer Meda Pharma Gmbh & Co. Kg
Maltese: Budesonid Novolizer Meda Pharma Gmbh & Co.
English: Montrose Kft
Maltese: L-Ungerija Montrose Kft
English: Budezonid Lek-Am Budesonide 400µg Inhalation
Maltese: Budezonid Lek-Am Budesonide Inalazzjoni ta' 400 µg
English: Beclometasone Dipropionate 0.2mg Dose
Maltese: Beclometasone Dipropionate Doża ta' 0.2mg
English: Salmeterol 25µg/Dose; Fluticasone Propionate 125µg/Dose
Maltese: Salmeterol 25 µg/Doża; Fluticasone Propionate 125 µg/Doża
English: Belgium Nv Astrazeneca Sa
Maltese: Il-Belġju Nv Astrazeneca Sa
English: Astrazeneca österreich Gmbh
Maltese: L-Awstrija Astrazeneca österreich Gmbh
English: Budezonid Lek-Am Budesonide 200µg Inhalation
Maltese: Budezonid Lek-Am Budesonide Inalazzjoni ta' 200 µg
English: Nasal Spray, Suspension
Maltese: Inalazzjoni taħt Pressjoni, Sospensjoni
English: Flunisolide 25mg Bottle, Salbutamol 10mg Bottle
Maltese: Flunisolide Flixkun ta' 25mg, Salbutamol Flixkun ta' 10mg
English: Astrazeneca Gmbh
Maltese: Il-Ġermanja Astrazeneca Gmbh
English: Salvus D.O.O.
Maltese: Il-Kroazja Salvus D.O.O.
English: Fluticasone Propionate 250µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose
Maltese: Fluticasone Propionate Doża ta' 250 µg, Salmeterol Doża ta' 50 µg, Lactose Monohydrate Doża ta' 24.677mg
English: 3m Health Care Ltd
Maltese: L-Awstrija 3m Health Care Ltd
English: Novartis, S.R.O.
Maltese: Is-Slovakkja Novartis, S.R.O.
English: Clenil Compositum Beclometasone Dipropionate 50µg Actuation, Salbutamol Sulfate 120µg Actuation
Maltese: Clenil Compositum Beclometasone Dipropionate Attwazzjoni ta' 50 µg, Salbutamol Sulfate Attwazzjoni ta' 120 µg
English: Belgium Orion Corporation
Maltese: Il-Belġju Orion Corporation
English: Glaxosmithkline Kft.
Maltese: L-Ungerija Glaxosmithkline Kft.
English: Flixotide Diskus Forte
Maltese: Kg Flixotide Forte Diskus
English: Fluticasone Propionate 500µg Dose, Salmeterol 50µg Dose, Lactose Monohydrate 24.677mg Dose
Maltese: Fluticasone Propionate Doża ta' 500 µg, Salmeterol Doża ta' 50 µg, Lactose Monohydrate Doża ta' 24.677mg
English: Ratiopharm Gmbh
Maltese: Il-Ġermanja Ratiopharm Gmbh
English: Luxembourg Chiesi Sa-Nv
Maltese: Il-Belġju Chiesi Sa-Nv
English: Budesonide 160µg Dose, Formoterol Fumarate Dihydrate Ph.Eur.
Maltese: Budesonide Doża ta' 160 µg, Formoterol Fumarate Dihydrate Ph.Eur.
English: Budesonide 320µg Dose, Formoterol Fumarate Dihydrate Ph.Eur.
Maltese: Budesonide Doża ta' 320 µg, Formoterol Fumarate Dihydrate Ph.Eur.
English: Sopharma Ad
Maltese: Il-Bulgarija Sopharma Ad
English: Budesonide 1mg Ampoule
Maltese: Budesonide Ampulla ta' 1mg
English: Netherlands Astrazeneca Bv
Maltese: Astrazeneca Bv
English: Pb Pharma Gmbh
Maltese: Il-Ġermanja Pb Pharma Gmbh
English: Sandoz D.O.O.
Maltese: Il-Kroazja Sandoz D.O.O.
English: Symbicort Mite Turbuhaler Budesonide 160µg Dose, Formoterol Fumarate Dihydrate 4.5µg Dose
Maltese: Symbicort Mite Turbuhaler Budesonide Doża ta' 160 µg, Formoterol Fumarate Dihydrate Doża ta' 4.5 µg
English: Budesonide, Micronised 0.4mg Actuation
Maltese: Budesonide, Attwazzjoni Mikronizzata ta' 0.4mg
English: Glaxosmithkline Eood
Maltese: Il-Bulgarija Glaxosmithkline Eood
English: Cyclocaps Beclometason Beclometasone Dipropionate 400µg Units
Maltese: Cyclocaps Beclometason Beclometasone Dipropionate Unitajiet ta' 400 µg
English: Netherlands Glaxosmithkline B.V.
Maltese: Glaxosmithkline B.V.
English: Budesonide 0.25mg Ampoule
Maltese: Budesonide 0.25mg Ampulla
English: Providens D.O.O.
Maltese: Il-Kroazja Providens D.O.O.
English: Chiesi Gmbh
Maltese: Il-Ġermanja Chiesi Gmbh
English: Formoterol Fumarate Dihydrate 6µg Dose, Beclometasone Dipropionate Anhydrous 100µg Dose
Maltese: Formoterol Fumarate Dihydrate Doża ta' 6 µg, Beclometasone Dipropionate Anhydrous Doża ta' 100 µg
English: Budesonide 200µg Puff
Maltese: Budesonide Puff ta' 200 µg
English: Belgium Glaxosmithkline Pharmaceuticals S.A.
Maltese: Il-Belġju Glaxosmithkline Pharmaceuticals S.A.
English: Glaxosmithkline Pharma A-S
Maltese: Id-Danimarka Glaxosmithkline Pharma A-S
English: Astrazeneca Oy
Maltese: Nv Astrazeneca Sa
English: Sandoz Gmbh
Maltese: L-Awstrija Sandoz Gmbh
English: Astrazeneca D.O.O
Maltese: Il-Kroazja Astrazeneca D.O.O
English: Glaxosmithkline D.O.O.
Maltese: Il-Kroazja Glaxosmithkline D.O.O.
English: Glaxosmithkline Oy
Maltese: Glaxosmithkline
English: Luxembourg Orion Corporation
Maltese: Il-Ġermanja Orion Corporation
English: Budesonide, Micronised 0.2mg Actuation
Maltese: Budesonide, Attwazzjoni Mikronizzata ta' 0.2mg